Opinion

Video

Unmet Needs in Relapsed or Refractory Multiple Myeloma

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Ke Ning, MD

Sarah Rockwell, PharmD, BCOP, and Ke Ning, MD, share their concluding remarks, reflecting on the current landscape and expressing their aspirations for addressing remaining unmet needs.

Related Videos
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
Related Content
Multiple Myeloma is a cancer of plasma cells, a type of white blood cell found in bone marrow - Image credit: kamonrat | stock.adobe.com
November 12th 2024

Bispecific Antibody Receives FDA Orphan Drug Designation for the Treatment of Multiple Myeloma

Kennedy Ferruggia, Assistant Editor
Pharmacy Focus: Oncology Edition
April 17th 2023

Pharmacy Focus: Oncology Edition - Consider Treatment Sequences Carefully in Myeloma

Image Credit: © CHA - stock.adobe.com
November 6th 2024

Bone Marrow Adipocytes May Offer Early Detection of MGUS Progression to Multiple Myeloma

Alexandra Gerlach, Associate Editor
Image Credit: © Сергей Косилко - stock.adobe.com
November 1st 2024

Carfilzomib, Lenalidomide, and Dexamethasone: A Curative Approach for Smoldering Multiple Myeloma

Alexandra Gerlach, Associate Editor
Biliary tract cancer -- Image credit: Thipphaphone | stock.adobe.com
October 30th 2024

Emerging Therapies and Precision Medicine Offer Promising Results in Hepatocellular Carcinoma and Biliary Tract Cancer

Gabriela Aponte-Melendez, PharmD Nicole Bentivegna, PharmD, BCOP
Multiple myeloma in bone marrow -- Image credit: Saiful52 | stock.adobe.com
October 24th 2024

Advances in CAR T-Cell Therapy and Bispecifics for Relapsed/Refractory Multiple Myeloma

Alana Hippensteele, Managing Editor